Wisdom Pharmaceutical Industry-B (02561.HK) announces its interim results. Research and development costs increased by 19.8% year-on-year to 46.621 million yuan.

Zh tng cijng APP xn, wishng yoy -B (02561.HK) fb jizh 2025 nin 6 yu 30 r zh li g yu zhngq yj, q ni qd qt shur 530.1 wn yun (rnmnb, xi tng); ynji j kif chngbn 4662.1 wn yun, tngb zngji 19.8%. Zhtng Financial APP News, Vesheng Pharmaceutical-B (02561.HK) released its interim performance for the six months ending June 30, 2025, with other income of 5.301 million yuan (RMB, likewise) obtained during the period; research and development costs amounted to 46.621 million yuan, an increase of 19.8% year-on-year.